[
    {
        "Gene name":"GNAS",
        "Genomic Position":"20:57427769-57486247(+) | 20q13.32",
        "CDS Mutation":null,
        "AA Mutation":"GNAS_R201H",
        "Disease":"Thyroid Gland Follicular Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radioactive Iodine",
        "Description":"A 79 year old patient with prior history of graves' disease presented with follicular thyroid carcinoma. Two mutations NRAS p.Q61K and GNAS p.R201H were detected. The thyroid cancer manifested as a 13.5 cm mass. There were minimal lung, humerus and T9 spine metastases, and exhibited a very good response to the radioactive iodine treatment after he had underwent total thyroidectomy and bilateral neck dissection. They also screened other 23 fatal cases and revealed that none of them had GNAS p.R201H mutation. But two of them had NRAS p.Q61K mutation.",
        "rs value":null,
        "pmid":"PubMed:26788326",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00984282",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00095693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib + Temsirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01025453",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01263951",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04238624",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05182931",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Lapatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01947023",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Pazopanib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01713972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"Thyroid Gland Anaplastic Carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib,Dabrafenib",
        "Description":"Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11\/16 patients with anaplastic thyroid carcinoma responded to treatment (overall response rate 69%; 95% CI, 41% to 89%). Seven patients had ongoing responses. Median duration of response, progression-free survival, and overall survival were not reached after 120 weeks.",
        "rs value":null,
        "pmid":"PubMed:29072975",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05099068",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04739566",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E\/K",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02034110",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E\/K",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Intensity modulated radiation therapy + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03975231",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Radioiodine + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03244956",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CDX-3379 + Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02456701",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"Thyroid Gland Papillary Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib",
        "Description":"Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positive papillary thyroid cancer that have become resistant to radioactive iodine (the standard treatment). There were 116 patients identified for this trial, 51 of which met the conditions to be included. These 51 patients were split into two cohorts: 1) patients that had never been treated with a multikinase inhibitor targeting VEGFR and 2) patients that have previously been treated with a VEGFR multikinase inhibitor. In cohort 1, ten of 26 patients had best overall response. Best overall response was defined as the proportion of patients with a complete or partial response, however these ten patients were all partial response. In the same cohort 1, nine had achieved stable disease control for at least six months; therefore, 19 patients achieved disease control (73% of total cohort 1, 95% CI 52-88). In cohort 2, of 23 eligible patients, six had a partial response as best overall response and six had stable disease control for at least six months; therefore, 12 patients achieved disease control. (55% of total cohort 2, 95% CI 32-76). The authors conclude that vemurafenib is a potential treatment option for late-stage BRAF V600E-positive papillary thyroid cancer for treatment in patients na\ufffd\ufffdve to a multikinase inhibitor (Cohort 1) and to patients that have been previously treated with a multikinase inhibitor (Cohort",
        "rs value":null,
        "pmid":"PubMed:27460442",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cobimetinib + Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03181100",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | papillary carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01877811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | papillary carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"XL281",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"thyroid | carcinoma | papillary carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01709292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | Langerhans cell histiocytosis",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cladribine + Cytarabine + Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03585686",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"Thyroid Gland Papillary Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib",
        "Description":"Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors. 51 patients were enrolled (26 cohort 1, 25 cohort 2). In cohort 1, partial response was achieved in ten (38.5%) patients. Nine patients achieved stable disease for at least 6 months (35%). Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months. In cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months. Median PFS was 8.9 months and median OS was 14.4. months.",
        "rs value":null,
        "pmid":"PubMed:27460442",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | Langerhans cell histiocytosis",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HLX208",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05092815",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01286753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HLX208",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05102292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"Thyroid Gland Anaplastic Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib",
        "Description":"In a phase 2 \ufffd\ufffd\ufffdbasket\ufffd\ufffd\ufffd study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete response and one partial response was observed, for a response ",
        "rs value":null,
        "pmid":"PubMed:26287849",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E\/M",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Encorafenib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04061980",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E\/M",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Encorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04061980",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"Thyroid Gland Anaplastic Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pertuzumab,Vemurafenib",
        "Description":"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant anaplastic thyroid cancer had a complete response.",
        "rs value":null,
        "pmid":"PubMed:29320312",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600E",
        "Disease":"Thyroid Gland Papillary Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib",
        "Description":"A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q. Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease.",
        "rs value":null,
        "pmid":"PubMed:24987354",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02034981",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02289144",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_Fusion",
        "Disease":"Thyroid Gland Anaplastic Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib",
        "Description":"A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor volume, and her response has been stable on follow-up.",
        "rs value":null,
        "pmid":"PubMed:24687827",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02383927",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_G12_or_HRAS_G13_or_HRAS_Q61_or_KRAS_G12_or_KRAS_G13_or_KRAS_Q61_or_NRAS_G12_or_NRAS_G13_or_NRAS_Q61",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radioiodine + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02152995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30036146",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BI 3011441",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04742556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Crolibulin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01240590",
        "source_db":"COSMIC"
    }
]